NASDAQ:APEN - Apollo Endosurgery Stock Price, Forecast & News

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Apollo Endosurgery Inc (NASDAQ:APEN) issued its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.40) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.02. The biotechnology company earned $11.26 million during the quarter, compared to analysts' expectations of $13.37 million. Apollo Endosurgery had a negative return on equity of 176.86% and a negative net margin of 71.59%. View Apollo Endosurgery's Earnings History.

Apollo Endosurgery is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Apollo Endosurgery.

1 brokerages have issued twelve-month price targets for Apollo Endosurgery's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Apollo Endosurgery's share price to reach $3.00 in the next year. This suggests a possible upside of 11.5% from the stock's current price. View Analyst Price Targets for Apollo Endosurgery.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery.

Media coverage about APEN stock has trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Apollo Endosurgery earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Apollo Endosurgery.

Apollo Endosurgery saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 194,500 shares, an increase of 5.1% from the October 31st total of 185,000 shares. Based on an average daily volume of 14,100 shares, the short-interest ratio is presently 13.8 days. Approximately 1.5% of the company's stock are sold short. View Apollo Endosurgery's Current Options Chain.

Some companies that are related to Apollo Endosurgery include Repro-Med Systems (REPR), Repro Med Systems (KRMD), Soliton (SOLY), iCAD (ICAD), TELA Bio (TELA), Cytosorbents (CTSO), BRAINSWAY LTD/S (BWAY), Restoration Robotics (HAIR), Spectral Medical (EDTXF), Neuronetics (STIM), Liquidia Technologies (LQDA), STRATA Skin Sciences (SSKN), Nephros (NEPH), Sensus Healthcare (SRTS) and Pro-Dex (PDEX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Corbus Pharmaceuticals (CRBP), Second Sight Medical Products (EYES), Genocea Biosciences (GNCA), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Anavex Life Sciences (AVXL) and Novavax (NVAX).

Apollo Endosurgery's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (1.25%). Company insiders that own Apollo Endosurgery stock include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Institutional Ownership Trends for Apollo Endosurgery.

APEN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View Insider Buying and Selling for Apollo Endosurgery.

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of APEN stock can currently be purchased for approximately $2.69.

Apollo Endosurgery has a market capitalization of $56.33 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.View Additional Information About Apollo Endosurgery.

The official website for Apollo Endosurgery is http://www.apolloendo.com/.

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]